ArticleAdvanced functional materials2025
Local administration of lipid-silica nanohybrid-carried forskolin modulates thermogenesis in human adipocytes and impedes weight gain in mice.
Article in Advanced functional materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Integrin α7 defines a profibrotic adipose stromal population targeted for nanoparticle PAI-1 gene silencing in obesity.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Theoretical and Experimental Investigation of Triphenylamine-Containing Hole Transport Materials with Side-Chain Isomerization.Journal of molecular modeling · 2026Article
- Bioactive Phytoconstituents Targeting Energy Expenditure and Appetite to Combat Obesity: A Comprehensive Review.Current nutrition reports · 2026Review
- Targeting cuproptosis opens a new chapter of nanomedicine: a scientometric and graphical analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Developing Nanoparticle-Based Therapeutics for Targeting the Microenvironment in Obesity-Induced Endometrial Cancer.Cellular and molecular bioengineering · 2025Article
- Emerging Nanotechnology Strategies for Obesity Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Anti-Obesity and Metabolic Effects of Forskolin in Obese C57BL/6J Mice.International journal of molecular sciences · 2025Article
- Rational Design of Safer Inorganic Nanoparticles via Mechanistic Modeling-Informed Machine Learning.ACS nano · 2025Article
- Rational Design of Safer Inorganic Nanoparticles via Mechanistic Modeling-informed Machine Learning.Research square · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Despite encouraging outcomes of the eight FDA approved drugs in lessening obesity burden, they have been associated with side effects caused by the lack of direct action on the adipose tissue. Therefore, we report a nanomedicine that promotes the transformation of local fat-storage white adipocytes, associated with obesity, into thermogenic adipocytes, indicative of enhanced metabolism, to both human cells and mice. Our nanomedicine consisting of a lipid-silica nanohybrid that allows accommodation of the natural supplement forskolin has resulted in successful browning of mature human adipocytes in vitro through upregulating thermogenesis biomarkers on mature human adipocytes and in vivo in mice tissue (achieving 400- and 80-fold increases in UCP1 and Cox7A1, respectively), while significantly enhancing glucose uptake and lipolysis in an acute fashion and significantly preventing weight gain in high fat diet (60% HFD) mice compared to other treatments including liposomal medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.